PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2006.38.1.35200638135Serum HER2 as a Response Indicator to Various Chemotherapeutic Agents in Tissue HER2 Positive Metastatic Breast CancerSun-Young Kong, Do Hoon Lee, Eun Sook Lee, Susan Park, Keun Seok Lee, Jungsil Rohttp://www.e-crt.org/upload/pdf/crt-38-35.pdf, http://www.e-crt.org/upload/pdf/crt-38-35.pdf
Handbook of HER2-Targeted Agents in Breast Cancer10.1007/978-3-319-28216-9_5201671-86HER2-positive metastatic breast cancer: second-line treatmentRicardo H. Alvarezhttp://link.springer.com/content/pdf/10.1007/978-3-319-28216-9_5
Handbook of HER2-Targeted Agents in Breast Cancer10.1007/978-3-319-28216-9_4201651-69HER2-positive metastatic breast cancer: first-line treatmentLeticia De Mattos-Arruda, Javier Cortéshttp://link.springer.com/content/pdf/10.1007/978-3-319-28216-9_4
Handbook of HER2-Targeted Agents in Breast Cancer10.1007/978-3-319-28216-9_6201687-110Emerging targeted agents for HER2-positive breast cancerDimitrios Zardavas, Martine Piccarthttp://link.springer.com/content/pdf/10.1007/978-3-319-28216-9_6
Handbook of HER2-Targeted Agents in Breast Cancer10.1007/978-3-319-28216-9_3201629-49HER2-positive breast cancer: neoadjuvant and adjuvant therapyNadia Harbeckhttp://link.springer.com/content/pdf/10.1007/978-3-319-28216-9_3
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00004-0201963-74HER2-Positive Breast CancerSarah Sammons, Kimberly Blackwellhttps://api.elsevier.com/content/article/PII:B9780323581226000040?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323581226000040?httpAccept=text/plain
Breast Diseases: A Year Book Quarterly10.1016/s1043-321x(07)80043-9200718163-641–33 Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast CancerM.Z. Gilcreasehttps://api.elsevier.com/content/article/PII:S1043321X07800439?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1043321X07800439?httpAccept=text/plain
Breast Care10.1159/0005169362021172146-152First-Line Efficacy of Anti-HER2 Treatments in Previously Treated HER2-Positive Metastatic Breast Cancer Patients: A Retrospective Observational Study Investigating the Efficacy of Re-Exposure to Anti-HER2 Therapy for HER2-Positive Metastatic Breast Cancer Patients in Comparison with Naïve PatientsBarliz Waissengrin, Roni Levin, Ido Wolf, Eliya Shachar, Amir Sonnenblickhttps://www.karger.com/Article/Pdf/516936, https://www.karger.com/Article/Pdf/516936
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00014-32019231-237Biosimilars for HER2-Positive Breast CancerHope S. Rugohttps://api.elsevier.com/content/article/PII:B9780323581226000143?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323581226000143?httpAccept=text/plain
The Breast10.1016/s0960-9776(15)30153-3201524S70PO141 SUCCESSFUL USE OF HER2 TARGETED AGENTS IN PATIENTS WITH HEAVILY PRETREATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTING WITH ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN AND/OR HER2 OVEREXPRESSING CIRCULATING TUMOR CELLSChristian Martin Kurbacher, Annegret Quade, Gerhard Kunstmann, Susanne Herz, Jutta Anna Kurbacher, Matthias R. Warmhttps://api.elsevier.com/content/article/PII:S0960977615301533?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977615301533?httpAccept=text/plain